newsfilter
← Latest News
Business Wire·

Alpine Immune Sciences Reports Second Quarter 2023 Financial Results

--The Company will present preliminary data from RUBY-3 glomerulonephritis clinical study at the American Society of Nephrology Meeting in November 2023-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading